Current etf page

ETF Context

XBI ETF Context

News · Liquidity · Exposure · AIQ Momentum

Financial ServicesAsset ManagementScore data as of Sep 4, 2026

XBI

ETF Context
State Street SPDR S&P Biotech ETF
Financial Services· Asset Management
AIQ Score
NeutralAIQ Edge 9/10
Relative Leader / Watch
Strong Relative Position
Score data as of Sep 4, 2026
Last price
$163.81
-$0.57 (-0.35%)
Latest market quote
Momentum65
Value
Quality66
Risk Resilience59
Sentiment
View financial data

ETF Context Board

News pressure, liquidity, fund structure, exposure, and AIQ momentum context.

Inception date
Jan 31, 2006

Equity fund profile date from the ETF info snapshot.

AIQ Context
AIQ 64/100

Momentum 65/100 and sentiment beside current fund and news context.

Recent coverage
3 articles

Updated Sep 6, 2026 · Sentiment 19.00%

ETF Context Read

ETF context should explain what can change the setup and which AIQ component would move first.

Current ETF setup

Primary exposureFinancial Services (0.40%)

Largest available fund exposure bucket.

Expense ratio0.35%

Cost context that can affect long-term fund returns.

Average volume10.68M

Liquidity context for entry and exit conditions.

Holdings source dateSep 5, 2026

Latest source date for reported holdings.

Holdings changeNot available

No reliable ETF buy/sell change feed in this snapshot.

Sentiment score

News pressure around the ETF setup.

Momentum score65

Where market reaction would show up first.

AIQ score64/100

Composite decision read before confirmation.

Fund context

Issuer
SPDR

Fund sponsor from the ETF info snapshot.

Asset class
Equity

Broad asset class for the ETF.

Primary exposure
Financial Services (0.40%)

Largest available exposure bucket.

Fund size
$11.49B

Current assets under management when provided.

Expense ratio
0.35%

Annual fund cost reported by the provider.

Holdings
154

Number of positions in the fund snapshot.

Average volume
10.68M

Liquidity context from the ETF info snapshot.

Holdings source date
Sep 5, 2026

Latest holder snapshot source date.

Holdings change
Not available

Current ETF holder rows do not include reliable buy/sell change fields.

Institutional report date
Jun 30, 2026

Latest downstream institutional-holder filing date.

Institutional share change
-15.02M

Net filing-reported change across available institutional holder rows.

Institutional Holder Changes

Filing-reported ETF share ownership changes by holder; this is not intraday flow or constituent trading.

Largest reported increases
HolderSharesChangeReported
GOLDMAN SACHS GROUP INC15.11M1.39MJun 30, 2026
GOLDMAN SACHS GROUP INC15.11M1.39MJun 30, 2026
TWO SIGMA INVESTMENTS, LP1.5M1.16MJun 30, 2026
TWO SIGMA INVESTMENTS, LP1.5M1.16MJun 30, 2026
CITIGROUP INC11.61M949.48KJun 30, 2026
CITIGROUP INC11.61M949.48KJun 30, 2026
WELLS FARGO & COMPANY/MN3.5M757.87KJun 30, 2026
WELLS FARGO & COMPANY/MN3.5M757.87KJun 30, 2026
Largest reported decreases
HolderSharesChangeReported
JPMORGAN CHASE & CO1.81M-4.43MJun 30, 2026
JPMORGAN CHASE & CO1.81M-4.43MJun 30, 2026
BNP PARIBAS ARBITRAGE, SNC16.78M-4.38MJun 30, 2026
BNP PARIBAS ARBITRAGE, SNC16.78M-4.38MJun 30, 2026
BANK OF AMERICA CORP /DE/10.57M-3.95MJun 30, 2026
BANK OF AMERICA CORP /DE/10.57M-3.95MJun 30, 2026
MORGAN STANLEY10.83M-1.5MJun 30, 2026
MORGAN STANLEY10.83M-1.5MJun 30, 2026

News And Sentiment

Recent ETF coverage, scored where source sentiment is available.

Positive
1
Neutral
1
Negative
1
seekingalpha.com · Sep 5, 2026

XBI: Big Pharma Can Keep The 76% Rally Going (NYSEARCA:XBI)

Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.

finance.yahoo.com · Aug 26, 2026

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

zacks.com · Aug 24, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Open full news and sentiment

XBI ETF Context FAQ

What are the next catalysts for XBI stock?

XBI's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move XBI stock?

Upcoming events that could move XBI include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could XBI's next earnings report affect the stock?

XBI's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive XBI stock higher?

XBI could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt XBI stock?

XBI could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.